Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nippon Zoki to Develop Its 1st Biologic by Licensing Bone Forming Promoting Drug from South Korean Biotech
October 2, 2019
- Eisai, US Merck Present Final PII Results for Lenvima/Keytruda Combo for Endometrial Cancer
October 2, 2019
- Tsuyoshi Mitsuhashi Appointed as New President of Konica Minolta Precision Medicine
October 2, 2019
- Opdivo Significantly Extends OS against Chemo in Esophageal Cancer
October 2, 2019
- Takara Bio Drops Oncolytic Virus Filing for Melanoma in Japan
October 1, 2019
- ADC-Keytruda Combo Shows ORR of 71% in 1st Line Bladder Cancer: Astellas/Seattle Genetics
October 1, 2019
- Avanir’s AVP-786 Misses Goals in PIII for Moderate-to-Severe Agitation in AD Patients
October 1, 2019
- Eisai, Nichi-Iko Team Up for Generic Business in China
October 1, 2019
- AZ to Focus on Asthma-COPD Overlap in Marketing Triple-Combo Therapy Breztri, Will Help GPs Make Diagnosis
September 30, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- Nippon Shinyaku Submits Sakigake DMD Drug Viltolarsen in Japan, Could Be Approved by March
September 27, 2019
- Meiji Seika’s Korean JV Passes GMP Inspection by PMDA, Preparing for Contract Production of Nesp Biosimilar
September 27, 2019
- Otsuka Files for Abilify Once-Monthly Injection for Bipolar Disorder in Japan
September 27, 2019
- Takeda’s Sakigake-Designated Narcolepsy Drug Prolongs Sleep Latency in PI
September 27, 2019
- Entyvio Shows Superiority to Humira in Clinical Remission in Comparison Study: Takeda
September 27, 2019
- Amid Slow Uptake, Sysmex Pitching Its Genomic Profiling via Close Communications with Hospitals, Govt: Exec
September 27, 2019
- Takeda’s TAK-620 Shows Antiviral Activities for CMV Infection in PII
September 26, 2019
- Biogen Japan Chairman Torii to Resign Sept. 30
September 26, 2019
- Chugai’s Comprehensive Genomic Profiling Test Approved for Companion Diagnostic for Lynparza
September 26, 2019
- Mylan EPD Submits Clinical Trial Application in Japan for PIII Study of Eyedrop Therapy for Cystinosis
September 26, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…